KetoAir breathalyzer update furnished by Avalon Globocare (Nasdaq: ALBT)

Rhea-AI Filing Summary

Avalon Globocare Corp. filed a current report to share that it issued a press release providing updates on its KetoAir™ breathalyzer device. The filing states that the press release, attached as an exhibit, is being furnished under Regulation FD, which is used to distribute important company information broadly and at the same time to all investors. The company also clarifies that this information is not considered “filed” for liability purposes under securities laws unless specifically incorporated into another filing.

false 0001630212 0001630212 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 20, 2026

AVALON GLOBOCARE CORP.

(Exact name of registrant as specified in its charter)

Delaware		001-38728		47-1685128
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

4400 Route 9 South, Suite 3100, Freehold, NJ 07728 

(Address of principal executive offices)

(732) 780-4400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.)

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALBT		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 7.01. Regulation FD Disclosure.

On January 20, 2026, the Company issued a press release announcing updates with respect to the KetoAir™ breathalyzer device.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information included in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release of the Company dated January 20, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AVALON GLOBOCARE CORP.
Dated: January 20, 2026	By:	/s/ Luisa Ingargiola
	Name:	Luisa Ingargiola
	Title:	Chief Financial Officer

2

FAQ

What did Avalon Globocare (ALBT) report in this 8-K filing?

Avalon Globocare reported that it issued a press release announcing updates related to its KetoAir™ breathalyzer device, and furnished that release as an exhibit.

What is the focus of Avalon Globocare’s latest press release about KetoAir™?

The press release focuses on updates regarding Avalon Globocare’s KetoAir™ breathalyzer device, according to the description in the 8-K report.

How did Avalon Globocare disclose the KetoAir™ update to investors?

The company used a Form 8-K under Regulation FD to furnish a press release as Exhibit 99.1, making the KetoAir™ update broadly available to investors.

Is the KetoAir™ press release considered filed for liability purposes?

No. Avalon Globocare states that the KetoAir™ press release and related information are furnished, not filed, and are not subject to Section 18 liability unless specifically incorporated into another filing.

Which exhibit in the Avalon Globocare 8-K contains the KetoAir™ update?

Exhibit 99.1 to the 8-K contains the Avalon Globocare press release dated January 20, 2026, which discusses updates on the KetoAir™ breathalyzer device.

Who signed Avalon Globocare’s 8-K regarding the KetoAir™ update?

The 8-K was signed on behalf of Avalon Globocare Corp. by Luisa Ingargiola, the company’s Chief Financial Officer.